BA
RIGL icon

Boston Advisors’s Rigel Pharmaceuticals RIGL Stock Holding History

Boston Advisors’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-9,887
Closed -$300K – 686
2015
Q4 		$300K Hold
9,887
– – 0.01% 578
2015
Q3 		$244K Buy
+9,887
New +$295K 0.01% 701

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Boston Advisors's RIGL Position: Q1 2016 in Review

Boston Advisors sold out of Rigel Pharmaceuticals (RIGL) in Q1 2016, closing a stake of 9,887 shares — an estimated $300K sold.

Boston Advisors first reported a position in RIGL in Q3 2015 and held it in 2 quarters. The position peaked at $300K in Q4 2015. 120 funds tracked by Wall St. Rank hold RIGL as of Q1 2016.

  • Boston Advisors reported no remaining Rigel Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • Boston Advisors sold 9,887 Rigel Pharmaceuticals shares in Q1 2016, an estimated $300K.
  • Boston Advisors first reported a position in Rigel Pharmaceuticals in Q3 2015 and held it in 2 quarters.
  • Boston Advisors's Rigel Pharmaceuticals position peaked at $300K in Q4 2015.
  • 120 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2016.

Based on Boston Advisors's 13F filing for Q1 2016, filed 20 Apr 2016.